Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Alissa Huberty

Physician Assistant Little Rock, AR Physician Assistant

NPI 1366801995 CMS profile 10417800

4301 W Markham St 610, Little Rock, AR 72205

Open in the dashboard

General payments

$7,617

351 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alissa Huberty of Little Rock, AR is reported in the CMS Open Payments database as having received $7,617 across 351 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,851 93
2024 General $2,397 123
2023 General $2,611 108
2022 General $757 27

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alissa Huberty
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Alissa Huberty were reported at $1,851. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Alissa Huberty Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $757 $155 $48–$522 $149
2023 $2,611 $167 $52–$557 $160
2024 $2,397 $178 $55–$600 $164
2025 $1,851 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Sun Pharmaceutical Industries Inc. $1,095 45 payments
  2. AbbVie, Inc. $959 50 payments
  3. Lilly USA, LLC $901 52 payments
  4. Regeneron Healthcare Solutions, Inc. $849 31 payments
  5. Janssen Biotech, Inc. $719 34 payments
  6. Incyte Corporation $649 25 payments
  7. Novartis Pharmaceuticals Corporation $602 28 payments
  8. E.R. Squibb & Sons, L.L.C. $430 24 payments
  9. LEO Pharma Inc. $380 16 payments
  10. Genzyme Corporation $185 4 payments
  11. Other $849 42 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $7,254 345 payments
  2. Education $363 6 payments
Products named General payments · program years 2022–2025
  1. TALTZ $760 49 payments
  2. TREMFYA $719 34 payments
  3. DUPIXENT Inflammation And Immunology $597 21 payments
  4. ILUMYA $584 22 payments
  5. OPZELURA $579 24 payments
  6. COSENTYX $562 26 payments
  7. SKYRIZI $520 30 payments
  8. SOTYKTU $430 24 payments
  9. OLUMIANT $373 26 payments
  10. DUPIXENT Immunology $325 6 payments
  11. Other $3,002 149 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

616

Median for Physician Assistant: 241

Drug cost

$184,517

Median for Physician Assistant: $4,110

Branded share of claims

12%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Taltz Autoinjector Ixekizumab Brand 17 $115,760
Dupixent Pen Dupilumab Brand 13 $54,854
Tacrolimus Generic 47 $3,130
Ketoconazole Generic 115 $2,474
Clobetasol Propionate Generic 38 $1,287
Fluocinonide Generic 26 $1,078
Fluocinolone Acetonide Fluocinolone/Shower Cap Brand 15 $952
Triamcinolone Acetonide Generic 90 $942
Doxycycline Hyclate Generic 42 $746
Tretinoin Generic 16 $722

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$49,524

Of which drugs: $5,899

Medicare patients

353

Average age 74

Services billed

1,275

230 women, 123 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 47%
Diabetes 27%
Ischemic heart disease 25%
Depression 24%
Chronic kidney disease 16%
Atrial fibrillation 15%
Heart failure 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) J7308 Office 12 19 $5,896

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
COSENTYX
  • Novartis Pharmaceuticals Corporation $318
$318 — —
TREMFYA
  • Janssen Biotech, Inc. $293
$293 — —
SKYRIZI
  • AbbVie, Inc. $210
$210 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $184
$184 — —
OPZELURA
  • Incyte Corporation $158
$158 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

351 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record